Segmentation by Form (Tablets, IV Solution, and Others); by Dosage Type (25mg, 50mg, and 100 mg); by Application (Hypertension, Angina, Arrhythmias, and Others); and by End-User (Hospital Pharmacies, Drug Store, Online Pharmacy, and Others) – Global Demand Analysis & Opportunity Outlook 2031
Buy Now
On the basis of geographical analysis, the global atenolol market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in Europe region is estimated to witness noteworthy growth over the forecast period, as the region has witnessed a sharp hike in the cases of heart related diseases. Moreover, efficient and inexpensive healthcare facilities in the developed countries are estimated to support the growth of the market.
The market in the North America region is anticipated to gain the largest market share throughout the forecast period owing to the increasing availability of advanced treatment and medications, coupled with the growing prevalence of cardiac diseases in the region. Approximately one in every 18 people, or 5% of the U.S. population has arrhythmia. Furthermore, as per the statistics by the Center for Disease Control and Prevention, in the U.S., 116 million individuals have hypertension, and in 2019, 0.5 million deaths were caused directly or indirectly by hypertension.
Get more information on this report: Request Sample PDF
The global atenolol market is further classified on the basis of region as follows:
North America (U.S. & Canada) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC (Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.
Our in-depth analysis of the global atenolol market includes the following segments:
By Form
By Dosage Type
By Application
By End-User
Growth Drivers
Challenges
September 23, 2021: ViiV Healthcare, collectively owned by GlaxoSmithKline plc, Pfizer Inc. and Shionogi announced approval of the U.S. Food and Drug Administration (FDA) for drug Cabotegravir.
October 3, 2018: Ipca Pharmaceuticals Inc., announced that it has acquired Bayshore Pharmaceuticals LLC, a sales and marketing company of FDA approved generic drug products in the United States of America.
In 2023, market players might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain.
Controlling Inflation has become the first priority for global economies from last quarter of 2022 and to be followed in 2023. With skewed economic situations, rise in interest rate by governments to control spending and inflation, spiked oil and gas prices, high inflation, geo-political issues including U.S. & China trade war, Russia-Ukraine conflict to intensify the global economic issues.
The interest rates in the U.S. may be less sensitive in 2023 as compared to 2022; sigh of relief for businesses. Positive business sentiments, healthy business balance sheets, growth in construction spending (private construction value in 2022 stood at $1,429.2 billion, 11.7 percent (±1.0 percent) above the $1,279.5 billion spent in 2021, Residential construction in 2022 was $899.1 billion, up by 13.3 percent (±2.1 percent) from $793.7 billion in 2021, non-residential construction touched $530.1 billion, 9.1 percent (±1.0 percent) above the $485.8 billion in 2021.) showcases minimal impact of recession in the country.
Similarly, spiked spending in the European and major Asia economics including, India, China & Japan to showcase less impact on the global demand.
Ans: Increasing prevalence of hypertension, angina, and other cardiac diseases are anticipated to boost the market growth.
Ans: The market is anticipated to attain a substantial CAGR over the forecast period, i.e., 2022 – 2031.
Ans: Easy availability of other drugs to treat hypertension is estimated to hamper the market growth.
Ans: The North America region is anticipated to provide more business opportunities over the forecast period owing to the increasing cases of hypertension in the region.
Ans: The major players in the market are Abbott Laboratories, F. Hoffmann-La Roche AG, Danaher Corporation, Bio-Rad Laboratories, Inc., Sysmex Corporation, Zydus Pharmaceuticals Inc., Ipca Laboratories Limited, and Siemens Healthineers AG.
Ans: The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
Ans: The market is segmented by form, dosage type, application, end-user, and by region.
Ans: The hypertension segment is anticipated to hold largest market size in value over the forecast period and display significant growth opportunities.
Submit Your Request For Proposal (RFP)
